🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Relapsed or Refractory Multiple Myeloma
Clinical trial register · United Kingdom · industry-sponsored

Relapsed or Refractory Multiple Myeloma Trials in the UK

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 4 Birmingham 2 Airdrie 2 Plymouth 2 Aberdeen 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC2 Celgene1 AbbVie1 Bristol-Myers Squibb1
Site city
London4 Birmingham2 Airdrie2 Plymouth2 Aberdeen1
All 24 cities
Target enrolment
to
5 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 3
606
Plymouth, Cringleford, Glasgow, Birmingham, Leeds, Taunton
2023-01-10
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
London, Sutton
2022-11-22
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
Celgene
Phase 3
810
Cambridge, Truro, Airdrie, London, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent
2022-09-20
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-uk/condition/relapsed-or-refractory-multiple-myeloma

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.